PTCT RSI Chart
Last 7 days
-8.8%
Last 30 days
15.9%
Last 90 days
23.4%
Trailing 12 Months
-44.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 927.6M | 0 | 0 | 0 |
2023 | 770.4M | 818.7M | 798.2M | 937.8M |
2022 | 569.4M | 618.2M | 696.6M | 698.8M |
2021 | 430.4M | 471.9M | 492.2M | 538.6M |
2020 | 321.7M | 311.4M | 358.4M | 380.8M |
2019 | 261.8M | 278.5M | 296.4M | 307.0M |
2018 | 203.7M | 224.5M | 236.3M | 264.2M |
2017 | 90.3M | 122.5M | 141.3M | 174.1M |
2016 | 48.2M | 57.0M | 70.2M | 82.7M |
2015 | 23.5M | 28.6M | 36.7M | 36.8M |
2014 | 36.8M | 31.6M | 17.0M | 25.2M |
2013 | 28.6M | 27.8M | 36.9M | 34.7M |
2012 | 113.1M | 115.9M | 36.7M | 33.9M |
2011 | 0 | 0 | 0 | 105.4M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 07, 2024 | golden lee scott | sold | -5,743 | 32.82 | -175 | evp & chief medical officer |
Apr 19, 2024 | klein matthew b. | sold | -83,668 | 24.894 | -3,361 | chief executive officer |
Apr 17, 2024 | pauwels eric | sold | -19,781 | 25.135 | -787 | chief executive officer |
Apr 17, 2024 | klein matthew b. | sold | -32,851 | 25.135 | -1,307 | chief executive officer |
Apr 02, 2024 | golden lee scott | sold | -14,922 | 28.37 | -526 | evp & chief medical officer |
Feb 15, 2024 | golden lee scott | acquired | - | - | 22,600 | chief medical officer |
Feb 15, 2024 | southwell david p | acquired | - | - | 4,000 | - |
Feb 15, 2024 | jacobson allan steven | acquired | - | - | 4,000 | - |
Feb 15, 2024 | almstead neil gregory | acquired | - | - | 870 | chief technical ops officer |
Feb 15, 2024 | bell william f. jr. | acquired | - | - | 4,000 | - |
Which funds bought or sold PTCT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | Empowered Funds, LLC | new | - | 2,420,170 | 2,420,170 | 0.02% |
May 07, 2024 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -14.04 | -145,000 | 1,425,000 | -% |
May 07, 2024 | Susquehanna Portfolio Strategies, LLC | reduced | -62.85 | -1,348,100 | 869,791 | 0.02% |
May 07, 2024 | Inspire Investing, LLC | reduced | -13.05 | -31,830 | 355,305 | 0.04% |
May 07, 2024 | Arizona State Retirement System | reduced | -1.54 | 20,538 | 542,965 | -% |
May 07, 2024 | PANAGORA ASSET MANAGEMENT INC | reduced | -4.7 | 48,901 | 8,398,340 | 0.04% |
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 118 | 880,112 | 1,554,400 | -% |
May 07, 2024 | Headlands Technologies LLC | reduced | -22.95 | -24,105 | 104,986 | 0.03% |
May 07, 2024 | Swiss National Bank | unchanged | - | 204,355 | 3,885,410 | -% |
May 06, 2024 | DUALITY ADVISERS, LP | added | 5.85 | 150,536 | 1,434,780 | 0.14% |
Unveiling PTC Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to PTC Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.7B | 6.8B | -7.83 | 6.82 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.01 | 9.62 | ||||
BMRN | 15.5B | 2.5B | 75.6 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -9.48 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.3 | 9.79 | ||||
AXSM | 3.6B | 251.0M | -12.15 | 14.35 | ||||
ARWR | 3.1B | 240.7M | -10.53 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 411.3M | 26.68 | 4.22 | ||||
NVAX | 625.6M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 451.6M | 881.7K | -13.38 | 481.06 | ||||
INO | 257.1M | 4.9M | -1.9 | 52.83 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
PTC Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -31.6% | 210,118,000 | 307,056,000 | 196,576,000 | 213,808,000 | 220,382,000 | 167,412,500 | 217,127,000 | 165,526,000 | 148,735,000 | 165,230,500 | 138,743,000 | 116,676,000 | 117,942,000 | 118,864,000 | 118,404,000 | 75,239,000 | 68,259,000 | 96,459,000 | 71,416,000 | 85,522,000 | 53,583,000 |
Operating Expenses | -15.2% | 255,571,000 | 301,236,000 | 314,740,000 | 423,351,000 | 337,997,000 | 367,752,000 | 285,314,000 | 257,888,000 | 235,257,000 | 249,958,500 | 231,819,000 | 215,169,000 | 216,090,000 | 215,238,000 | 173,535,000 | 262,512,000 | 161,250,000 | 169,243,000 | 131,891,000 | 124,280,000 | 122,723,000 |
S&GA Expenses | -4.0% | 73,272,000 | 76,291,000 | 80,886,000 | 88,449,000 | 86,914,000 | 92,717,500 | 80,118,000 | 79,892,000 | 73,271,000 | 86,548,000 | 69,252,000 | 68,878,000 | 61,095,000 | 75,456,000 | 57,840,000 | 53,659,000 | 58,209,000 | 63,497,500 | 49,284,000 | 49,215,000 | 40,544,000 |
R&D Expenses | -4.3% | 116,129,000 | 121,353,000 | 164,212,000 | 185,874,000 | 195,124,000 | 188,693,500 | 165,462,000 | 157,263,000 | 140,078,000 | 149,844,000 | 130,845,000 | 125,482,000 | 134,513,000 | 118,013,000 | 92,998,000 | 176,525,000 | 90,107,000 | 81,831,000 | 63,076,000 | 59,979,000 | 52,566,000 |
EBITDA Margin | 11.7% | -0.40 | -0.45 | -0.62 | -0.60 | -0.56 | -0.63 | -0.60 | -0.71 | -0.75 | -0.83 | -0.76 | -0.62 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 73.7% | 3,666,000 | 2,111,000 | 11,710,000 | 9,354,000 | 12,956,000 | 5,784,000 | 4,406,000 | 2,143,000 | 6,130,000 | -1,000 | 4,407,000 | - | 5,182,000 | - | 4,516,000 | 408,000 | 4,878,000 | 651,000 | 3,931,000 | - | 3,111,000 |
Income Taxes | 646.5% | 6,880,000 | -1,259,000 | -33,620,000 | -38,596,000 | 3,969,000 | -18,804,000 | -17,893,000 | 3,392,000 | 4,835,000 | 4,657,500 | -36,000 | 488,000 | 451,000 | 12,634,000 | 22,288,000 | 84,000 | 222,000 | 10,644,000 | -344,000 | 774,000 | 576,000 |
Earnings Before Taxes | 46.1% | -84,696,000 | -157,051,000 | -166,590,000 | -237,479,000 | -134,990,000 | -189,693,000 | -127,208,000 | -148,695,000 | -121,891,000 | -138,607,500 | -133,660,000 | -117,882,000 | -128,191,000 | -61,720,000 | -47,404,000 | -181,343,000 | -112,465,000 | -67,033,000 | -60,341,000 | -41,015,000 | -71,537,000 |
EBT Margin | 6.2% | -0.70 | -0.74 | -0.91 | -0.84 | -0.78 | -0.84 | -0.77 | -0.88 | -0.90 | -0.96 | -0.90 | -0.75 | - | - | - | - | - | - | - | - | - |
Net Income | 41.2% | -91,576,000 | -155,792,000 | -132,970,000 | -198,883,000 | -138,959,000 | -170,889,000 | -109,315,000 | -152,087,000 | -126,726,000 | -143,265,000 | -133,624,000 | -118,370,000 | -128,642,000 | -74,354,000 | -69,692,000 | -181,427,000 | -112,687,000 | -77,677,000 | -59,997,000 | -41,789,000 | -72,113,000 |
Net Income Margin | 6.5% | -0.62 | -0.67 | -0.80 | -0.75 | -0.74 | -0.80 | -0.76 | -0.90 | -0.92 | -0.97 | -0.92 | -0.83 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 157.8% | 61,173,000 | -105,854,000 | -20,876,000 | -20,365,000 | -39,761,000 | -174,585,000 | -43,427,000 | -63,942,000 | -106,716,000 | -77,566,000 | -57,034,000 | -39,119,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -5.6% | 1,790 | 1,896 | 1,260 | 1,338 | 1,609 | 1,706 | 1,576 | 1,804 | 1,800 | 1,938 | 2,007 | 2,059 | 2,112 | 2,208 | 2,181 | 1,477 | 1,546 | 1,624 | 1,641 | 1,292 | 1,284 |
Current Assets | -4.1% | 1,169 | 1,219 | 540 | 590 | 613 | 694 | 517 | 695 | 774 | 954 | 1,011 | 1,066 | 1,122 | 1,232 | 1,244 | 605 | 692 | 779 | 807 | 475 | 479 |
Cash Equivalents | -7.7% | 548 | 594 | 165 | 208 | 234 | 296 | 121 | 174 | 152 | 197 | 197 | 185 | 154 | 216 | 441 | 166 | 131 | 296 | 531 | 136 | 201 |
Inventory | -1.7% | 30.00 | 31.00 | 36.00 | 32.00 | 27.00 | 22.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 16.00 | 16.00 | 19.00 | 19.00 | 18.00 | 19.00 | 19.00 | 17.00 | 17.00 | 16.00 |
Net PPE | 6.5% | 93.00 | 87.00 | 85.00 | 82.00 | 79.00 | 73.00 | 67.00 | 65.00 | 59.00 | 53.00 | 46.00 | 43.00 | 37.00 | 34.00 | 28.00 | 27.00 | 26.00 | 22.00 | 18.00 | 15.00 | 15.00 |
Goodwill | 0.0% | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 | 82.00 |
Liabilities | -1.1% | 2,684 | 2,714 | 1,931 | 1,917 | 2,066 | 2,053 | 1,803 | 1,986 | 1,890 | 1,937 | 1,902 | 1,862 | 1,819 | 1,726 | 1,670 | 904 | 1,017 | 1,029 | 978 | 803 | 771 |
Current Liabilities | -4.7% | 575 | 603 | 492 | 476 | 442 | 406 | 420 | 567 | 477 | 509 | 465 | 291 | 251 | 277 | 254 | 202 | 218 | 236 | 184 | 174 | 143 |
Long Term Debt | 0.1% | 285 | 284 | 573 | 573 | 572 | 572 | 283 | 282 | 282 | 282 | 282 | 430 | 430 | 309 | 303 | 297 | 295 | 294 | 293 | 136 | 138 |
LT Debt, Current | - | - | - | - | - | - | - | - | 150 | 150 | 150 | 149 | - | - | 8.00 | - | 18.00 | 20.00 | 20.00 | 20.00 | 20.00 | 17.00 |
LT Debt, Non Current | 0.1% | 285 | 284 | 573 | 573 | 572 | 572 | 283 | 282 | 282 | 282 | 282 | 430 | 430 | 309 | 303 | 297 | 295 | 294 | 293 | 136 | 138 |
Shareholder's Equity | -9.2% | -893 | -818 | - | - | -457 | -347 | - | - | - | 1.00 | 105 | 197 | 293 | 482 | 511 | 572 | 529 | 594 | 664 | 489 | 513 |
Retained Earnings | -2.8% | -3,375 | -3,283 | -3,127 | -2,994 | -2,795 | -2,656 | -2,486 | -2,376 | -2,224 | -2,097 | -1,954 | -1,821 | -1,702 | -1,628 | -1,554 | -1,484 | -1,303 | -1,190 | -1,112 | -1,052 | -1,011 |
Additional Paid-In Capital | 0.8% | 2,487 | 2,466 | 2,447 | 2,417 | 2,340 | 2,305 | 2,223 | 2,184 | 2,153 | 2,124 | 2,093 | 2,064 | 2,034 | -123 | 2,101 | 2,067 | 1,834 | 1,795 | 1,776 | 1,540 | 1,523 |
Shares Outstanding | 1.2% | 77.00 | 76.00 | 75.00 | 75.00 | 74.00 | 73.00 | 71.00 | 71.00 | 71.00 | 70.00 | 71.00 | 70.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 2,331 | - | - | - | 2,130 | - | - | - | 2,191 | - | - | - | 2,923 | - | - | - | 2,567 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 170.6% | 71.00 | -100 | -14.52 | -14.12 | -29.49 | -165 | -38.04 | -55.24 | -97.40 | -68.84 | -51.19 | -31.14 | -100 | -64.37 | 27.00 | -74.81 | -81.55 | -10.21 | -15.50 | -30.52 | -42.41 |
Share Based Compensation | 11.3% | 18.00 | 17.00 | 27.00 | 29.00 | 29.00 | 27.00 | 29.00 | 28.00 | 27.00 | 26.00 | 26.00 | 26.00 | 26.00 | 21.00 | 17.00 | 17.00 | 15.00 | 11.00 | 10.00 | 11.00 | 9.00 |
Cashflow From Investing | -21.7% | -114 | -94.42 | -29.60 | -23.75 | -28.97 | 32.00 | 136 | 72.00 | 49.00 | 68.00 | 65.00 | 56.00 | 30.00 | -208 | -394 | 142 | -101 | -229 | 30.00 | -38.17 | -150 |
Cashflow From Financing | -99.9% | 1.00 | 620 | 3.00 | 18.00 | 4.00 | 303 | -139 | 4.00 | 1.00 | 4.00 | 3.00 | 4.00 | 10.00 | 40.00 | 643 | -32.92 | 18.00 | 2.00 | 382 | 3.00 | 226 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Revenue | $ 210,118 | $ 220,382 |
Operating expenses: | ||
Cost of product sales, excluding amortization of acquired intangible assets | 14,740 | 14,144 |
Amortization of intangible assets | 51,530 | 39,415 |
Research and development | 116,129 | 195,124 |
Selling, general and administrative | 73,272 | 86,914 |
Change in the fair value of contingent consideration | (100) | 2,400 |
Total operating expenses | 255,571 | 337,997 |
Loss from operations | (45,453) | (117,615) |
Interest expense, net | (40,834) | (27,331) |
Other income, net | 1,591 | 9,956 |
Loss before income tax expense | (84,696) | (134,990) |
Income tax expense | (6,880) | (3,969) |
Net loss attributable to common stockholders | $ (91,576) | $ (138,959) |
Weighted-average shares outstanding: | ||
Basic | 76,496,127 | 73,729,284 |
Diluted | 76,496,127 | 73,729,284 |
Net loss per share-basic and diluted (in dollars per share) | ||
Basic | $ (1.20) | $ (1.88) |
Diluted | $ (1.20) | $ (1.88) |
Net product revenue | ||
Revenues: | ||
Revenue | $ 177,604 | $ 187,557 |
Collaboration revenue | ||
Revenues: | ||
Revenue | 6 | |
Royalty revenue | ||
Revenues: | ||
Revenue | 31,154 | 30,831 |
Manufacturing revenue | ||
Revenues: | ||
Revenue | $ 1,360 | $ 1,988 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 548,355 | $ 594,001 |
Marketable securities | 336,458 | 282,738 |
Trade and royalty receivables, net | 197,660 | 160,822 |
Inventory, net | 30,058 | 30,577 |
Prepaid expenses and other current assets | 56,207 | 150,491 |
Total current assets | 1,168,738 | 1,218,629 |
Fixed assets, net | 92,779 | 87,089 |
Intangible assets, net | 330,040 | 379,497 |
Goodwill | 82,341 | 82,341 |
Operating lease ROU assets | 91,186 | 91,896 |
Deposits and other assets | 24,545 | 36,246 |
Total assets | 1,789,629 | 1,895,698 |
Current liabilities: | ||
Accounts payable and accrued expenses | 330,924 | 391,983 |
Deferred revenue | 801 | |
Operating lease liabilities- current | 14,572 | 13,002 |
Finance lease liabilities- current | 1,948 | 3,000 |
Liability for sale of future royalties - current | 227,102 | 194,314 |
Total current liabilities | 574,546 | 603,100 |
Long-term debt | 284,512 | 284,213 |
Contingent consideration payable | 36,200 | 36,300 |
Deferred tax liability | 55,904 | 55,905 |
Operating lease liabilities- noncurrent | 104,837 | 97,627 |
Finance lease liabilities- noncurrent | 15,574 | 17,184 |
Liability for sale of future royalties- noncurrent | 1,611,831 | 1,619,783 |
Other long-term liabilities | 141 | 141 |
Total liabilities | 2,683,545 | 2,714,253 |
Stockholders' deficit: | ||
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,653,960 shares at March 31, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023 | 76 | 75 |
Additional paid-in capital | 2,486,722 | 2,466,233 |
Accumulated other comprehensive loss | (5,560) | (1,285) |
Accumulated deficit | (3,375,154) | (3,283,578) |
Total stockholders' deficit | (893,916) | (818,555) |
Total liabilities and stockholders' deficit | $ 1,789,629 | $ 1,895,698 |